Given the increasing incidence of genital HSV-1,

we must consider a vaccination strategy that will provide cross-protection against both HSV-1 and HSV-2, which may ultimately shift the optimal timing of vaccination from adolescence to childhood. Finally, prophylactic vaccines must be tested in populations with high prevalence and incidence of genital HSV-2, as this will provide the benefit of rapid evaluation of candidate vaccine in the populations where HA-1077 manufacturer it is most desperately needed. CJ, DMK, and AW receive research funding from NIH. CJ has received research funding from AiCuris. DMK is listed as a co-inventor on patents describing T-cell responses to HSV-2, receives funding from Immune Design Corporation, and is a consultant to Agenus Inc and EISAI. AW has received research funding from Gilead, Agenus, Genentech and Genocea. She has been a consultant for Aicuris. CJ and AW receive royalties from UpToDate. The authors alone are responsible for the views expressed in this article and do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. “
“At an NIAID workshop entitled “Next Generation Herpes Simplex Virus Vaccines: The Challenges and Opportunities” on October 22–23, 2012, researchers agreed that

there was a great medical need for a herpes simplex virus (HSV) vaccine and recommended increased focus on all stages of herpes SP600125 cost vaccine research, development, and testing, including basic vaccine discovery research, development and manufacturing

of vaccines, human immunology, and clinical trials. While the need for an HSV vaccine has been recognized for decades, in the last 17 years only recombinant HSV glycoprotein D (gD) alone or with gB has been tested in randomized, double-blind, placebo controlled human trials to prevent genital herpes. In 2012, the results of the Herpevac Trial for Women, the largest HSV vaccine trial to date, involving over 8000 women who were seronegative for HSV-1 and HSV-2 were reported. The vaccine failed to reach its primary endpoint, reduction in occurrence of genital herpes disease due to either HSV-1 or HSV-2. While there was modest reduction Thiamine-diphosphate kinase in HSV-1 genital disease, there was no reduction in HSV-2 genital disease. The goal of the meeting was to reassess the status of the field, identify gaps in knowledge, and propose new approaches and solutions to fill the gaps. The medical need for a herpes vaccine was summarized as: 1. Morbidity caused by herpes infections. There are 500,000 cases of oral herpes and 300,000 cases of genital herpes each year in the US. These include 20,000 cases of ocular herpes and 1500 cases of central nervous system disease.